[go: up one dir, main page]

PE20061016A1 - Una formulacion solida de dosificacion farmaceutica - Google Patents

Una formulacion solida de dosificacion farmaceutica

Info

Publication number
PE20061016A1
PE20061016A1 PE2006000216A PE2006000216A PE20061016A1 PE 20061016 A1 PE20061016 A1 PE 20061016A1 PE 2006000216 A PE2006000216 A PE 2006000216A PE 2006000216 A PE2006000216 A PE 2006000216A PE 20061016 A1 PE20061016 A1 PE 20061016A1
Authority
PE
Peru
Prior art keywords
pharmaceutical dosage
solid pharmaceutical
dosage formulation
lopinavir
ritonavir
Prior art date
Application number
PE2006000216A
Other languages
English (en)
Inventor
Joerg Rosenberg
Gunther Berndl
Ulrich Reinhold
Bernd Liepold
Laman L Alani
Jorg Breitenbach
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36678380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20061016A1 publication Critical patent/PE20061016A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) LOPINAVIR EN UNA DISPERSION SOLIDA O SOLUCION SOLIDA QUE PROVEE UN PERFIL DE DISOLUCION IN VITRO USANDO UN APARATO 2 DE LA USP A 37°C ENTRE 75,4% Y APROXIMADAMENTE 93,2% DE LOPINAVIR ENTRE 45-60 MINUTOS; Y B) RITONAVIR CUYO PERFIL DE DISOLUCION IN VITRO USANDO UN APARATO 2 DE LA USP A 37°C ENTRE 73,4% Y 95% DE RITONAVIR ENTRE 45-60 MINUTOS. DICHA COMPOSICION ESTA EN UNA PROPORCION DE 4:1 Y SON UTILES EN EL TRATAMIENTO DE VIH/SIDA
PE2006000216A 2005-02-23 2006-02-22 Una formulacion solida de dosificacion farmaceutica PE20061016A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/064,467 US8377952B2 (en) 2003-08-28 2005-02-23 Solid pharmaceutical dosage formulation

Publications (1)

Publication Number Publication Date
PE20061016A1 true PE20061016A1 (es) 2006-10-03

Family

ID=36678380

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009001179A PE20100123A1 (es) 2005-02-23 2006-02-22 Una formulacion solida de dosificacion farmaceutica
PE2006000216A PE20061016A1 (es) 2005-02-23 2006-02-22 Una formulacion solida de dosificacion farmaceutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2009001179A PE20100123A1 (es) 2005-02-23 2006-02-22 Una formulacion solida de dosificacion farmaceutica

Country Status (39)

Country Link
US (3) US8377952B2 (es)
EP (4) EP1855683A2 (es)
JP (1) JP5087409B2 (es)
KR (1) KR101429024B1 (es)
CN (1) CN101163479B (es)
AR (2) AR055734A1 (es)
AU (1) AU2006216856B2 (es)
BR (2) BR122012031169A2 (es)
CA (2) CA2821046C (es)
CL (3) CL2009001844A1 (es)
CR (1) CR9353A (es)
CY (2) CY1120377T1 (es)
DK (2) DK2206500T3 (es)
DO (2) DOP2006000050A (es)
EA (1) EA014446B1 (es)
ES (2) ES2694073T3 (es)
GE (1) GEP20105083B (es)
GT (2) GT200600295AA (es)
HR (2) HRP20180999T1 (es)
HU (2) HUE038073T2 (es)
IL (1) IL185390A (es)
LT (2) LT2283844T (es)
MX (1) MX2007010275A (es)
MY (1) MY146247A (es)
NO (1) NO20074807L (es)
NZ (2) NZ599361A (es)
PE (2) PE20100123A1 (es)
PH (1) PH12012501811A1 (es)
PL (2) PL2206500T3 (es)
PT (2) PT2206500T (es)
RS (2) RS57378B1 (es)
SI (2) SI2283844T1 (es)
SV (1) SV2007002427A (es)
TR (2) TR201816268T4 (es)
TW (1) TWI381840B (es)
UA (1) UA89220C2 (es)
UY (2) UY29391A1 (es)
WO (1) WO2006091529A2 (es)
ZA (1) ZA200707022B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005115343A2 (de) * 2004-05-28 2005-12-08 Abbott Gmbh & Co. Kg Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
JP2009502969A (ja) * 2005-07-28 2009-01-29 アイエスピー インヴェストメンツ インコーポレイテッド 非晶質エファビレンツ及びその製造
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
WO2008029417A2 (en) * 2006-09-04 2008-03-13 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (en) * 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
EP2152244B1 (en) * 2007-04-26 2015-12-02 Technion Research & Development Foundation Ltd. Oral administration of proteins and peptides
EP2188265A1 (en) * 2007-08-07 2010-05-26 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
NZ584968A (en) * 2007-10-29 2012-11-30 Cipla Ltd Novel antiretroviral combination comprising ritonavir and atazanavir
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
US20100021540A1 (en) * 2008-02-28 2010-01-28 Abbott Laboratories Tablets and Preparation Thereof
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
WO2011013110A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
EP2279728A1 (en) 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
ES2699183T3 (es) * 2010-05-10 2019-02-07 Hetero Research Foundation Composiciones de darunavir
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2564832A1 (en) * 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
KR20150021510A (ko) * 2012-05-03 2015-03-02 시플라 리미티드 항레트로바이러스 조성물
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
EP2958563A2 (en) * 2013-02-20 2015-12-30 AbbVie Inc. Tablet dosage form comprising ritonavir and lopinavir
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
WO2020122243A1 (ja) * 2018-12-14 2020-06-18 富士フイルム株式会社 医薬組成物及びその製造方法
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
EP4153145A4 (en) * 2020-05-18 2024-05-29 Board of Regents, The University of Texas System Granules for 3d printing technology
CN112263554B (zh) * 2020-10-22 2022-09-30 安徽贝克生物制药有限公司 一种洛匹那韦利托那韦复方片剂及其制备方法

Family Cites Families (405)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE973095C (de) 1955-01-19 1959-12-03 Kalle & Co Ag Verfahren zur UEberfuehrung von OElen in streufaehige Pulver durch Spruehtrocknung von OEl-in-Wasser-Emulsionen
HU176101B (en) 1977-12-29 1980-12-28 Gyogyszerkutato Intezet Process for producing bis-bracket-nitrozo-ureido-bracket closed-polyol derivatives
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
JPS61205208A (ja) 1985-03-08 1986-09-11 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の速溶性製剤
US4590065A (en) 1985-04-18 1986-05-20 Colgate-Palmolive Company Stable flavor-containing dentifrice
US4758427A (en) 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
PH22025A (en) 1985-08-19 1988-05-13 Johnson & Son Inc S C Aqueous pyrethroid insecticidal formulations and method of increasing the stability thereof
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
ES2040697T3 (es) * 1986-12-18 1993-11-01 Kurt H. Prof. Dr. Bauer Concentrado de nifedipina estabilizado frente a la influencia de la luz, y procedimiento para su preparacion.
US4804699A (en) * 1987-05-15 1989-02-14 Ici Americas Inc. Monomeric and oligomeric glutarate-based light stabilizers for plastics
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
AU2902289A (en) 1987-12-08 1989-07-05 Mark Chasin Method of forming bioerodible implants for improved controlled drug release
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
GB8903328D0 (en) 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
HU204529B (en) 1989-08-10 1992-01-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them
US5075291A (en) 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
JPH07501259A (ja) 1990-06-01 1995-02-09 リサーチ　コーポレイション　テクノロジーズ，インコーポレイテッド 自己乳化型ガラス
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
EP0559896B1 (en) 1990-11-28 1997-08-27 Taisho Pharmaceutical Co. Ltd 6-o-methylerythromycin a derivative
ATE159426T1 (de) 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
WO1993007859A1 (en) 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
CA2124821C (en) 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Novel solid pharmaceutical dispersions
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
WO1993015736A1 (en) 1992-02-18 1993-08-19 Pharmos Corp. Dry compositions for preparing submicron emulsions
US5654003A (en) 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
MX9301817A (es) 1992-03-30 1994-01-31 Alza Corp Sistema polimerico que contiene un compuesto parcialmente soluble.
CA2095776C (en) * 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
IT1256026B (it) 1992-06-12 1995-11-20 Sali del glutatione etilestere
DE4220782A1 (de) * 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
DE4226753A1 (de) 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
GB9306887D0 (en) 1993-04-01 1993-05-26 Graham Neil B Random block copolymers
WO1995005809A1 (en) 1993-08-20 1995-03-02 Nippon Shinyaku Co., Ltd. Gastric remaining preparation, swollen molding, and production process
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
DE69434626D1 (de) * 1993-11-17 2006-04-20 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
JP4194114B2 (ja) 1994-02-23 2008-12-10 ビーエム リサーチ エイ／エス 制御放出組成物
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5443178A (en) 1994-06-23 1995-08-22 Allergan, Inc. Tablet dispensing system
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
CA2197327A1 (en) 1994-09-30 1996-04-11 Shigeyuki Takada Oral sustained-release preparation
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4446470A1 (de) * 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
DE4446468A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von umhüllten Tabletten
DE4446467A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von linsenförmigen Tabletten durch Schmelzkalandrierung
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
DE19500977C2 (de) 1995-01-14 1999-01-07 Lohmann Therapie Syst Lts Feste Arzneimittelform mit in polymerem Material verteiltem Wirkstoff
NZ270439A (en) 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19509805A1 (de) 1995-03-21 1996-09-26 Basf Ag Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CA2228610C (en) 1995-08-17 2008-06-03 Heidi Rolfes Controlled release products
DE19531277A1 (de) 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
US6391338B1 (en) 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE19536387A1 (de) 1995-09-29 1997-04-03 Basf Ag Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
WO1997013503A1 (en) 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
DE19602206A1 (de) 1996-01-23 1997-07-24 Basf Ag Zubereitungen nichtsteroidaler Analgetika
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
GB2311027B (en) 1996-03-15 1999-10-27 Johnson & Johnson Medical Coated bioabsorbable beads for wound treatment
US20030064108A1 (en) 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
DE19617716A1 (de) 1996-05-03 1997-11-06 Basf Ag In wäßriger Lösung redispergierbare Polymerpulver
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6764690B2 (en) 1996-05-29 2004-07-20 Delsitech Oy Dissolvable oxides for biological applications
WO1997046222A1 (en) 1996-06-03 1997-12-11 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
DE19624607A1 (de) 1996-06-20 1998-01-02 Basf Ag Verfahren zur Herstellung von Salzen von Säuregruppen tragenden pharmazeutischen Wirkstoffen
ES2325046T3 (es) 1996-06-26 2009-08-24 The Board Of Regents, The University Of Texas System Formulacion farmaceutica extruible por fusion en caliente.
DE19629753A1 (de) 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19635676A1 (de) 1996-09-03 1998-03-05 Basf Ag Feste geschäumte Wirkstoffzubereitungen
DE19637479A1 (de) 1996-09-13 1998-03-19 Basf Ag Verfahren zur Herstellung fester pharmazeutischer Formen
HRP970485A2 (en) 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US6071539A (en) 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
US5727878A (en) * 1996-10-17 1998-03-17 Cdf Corporation Liner for a mixing container and an assembly and method for mixing fluid components
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
HUP0000279A3 (en) 1996-11-15 2002-07-29 Merck Patent Gmbh Method for producing shaped and unshaped polyol masses
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6197787B1 (en) * 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
DE19709663A1 (de) 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen
DE19710009A1 (de) 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
DE19710213A1 (de) 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
US5948426A (en) 1997-05-03 1999-09-07 Jefferies; Steven R. Method and article to induce hematopoietic expansion
US6610764B1 (en) 1997-05-12 2003-08-26 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
DE19721467A1 (de) 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US5955475A (en) 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
JPH1125076A (ja) 1997-06-30 1999-01-29 Fujitsu Ltd 文書管理装置および文書管理プログラム記憶媒体
US5889051A (en) * 1997-07-15 1999-03-30 Development Center For Biotechnology Stabilization of prostaglandin drug
DE19733505A1 (de) 1997-08-01 1999-02-04 Knoll Ag Schnell wirksames Analgeticum
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
HN1998000115A (es) 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
EP1028712B1 (en) 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
JP3460538B2 (ja) 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
PT1033975E (pt) 1997-11-28 2002-07-31 Knoll Ag Processo para a preparacao de substancias biologicamente activas nao-cristalinas isentas de dissolventes
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
JPH11271927A (ja) * 1998-01-20 1999-10-08 Mitsubishi Paper Mills Ltd 画像材料用支持体
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US6589554B1 (en) 1998-03-16 2003-07-08 Yamanouchi Pharmaceutical Co., Ltd. Tablets quickly disintegrating in the oral cavity and process for producing the same
DE19812688A1 (de) 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19814730A1 (de) 1998-04-02 1999-10-07 Basf Ag Verwendung von N-Vinyllacram oder N-Vinylamin haltigen Copolymeren als Matrix zur Herstellung von festen pharmazeutischen und kosmetischen Darreichungsformen
DE19814739A1 (de) 1998-04-02 1999-10-07 Basf Ag Verwendung von Polyalkylenoxid-haltigen Pfropfpolymerisaten als Solubilisatoren
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
JP4568426B2 (ja) 1998-04-08 2010-10-27 協和発酵キリン株式会社 錠剤の製造方法及び錠剤
EP1073693A1 (en) 1998-04-24 2001-02-07 Eastman Chemical Company Coprecipitation of cellulose esters with functional additives and compositions thus obtainable
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
AU771960B2 (en) 1998-06-05 2004-04-08 Forbes Medi-Tech Inc. Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability
WO1999063971A1 (en) 1998-06-11 1999-12-16 Em Industries, Inc. Micro-osmotic controlled drug delivery systems
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US20010021372A1 (en) 1998-08-18 2001-09-13 Tore Omtveit Apparatus having partially gold-plated surface
DE19839276A1 (de) 1998-08-28 2000-03-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19840256A1 (de) * 1998-09-03 2000-03-09 Basf Ag Verfahren zur Herstellung von beschichteten festen Dosierungsformen
DE19841244A1 (de) 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
DE19842914A1 (de) 1998-09-18 2000-03-23 Basf Ag Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
DE19843904A1 (de) 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
US20040013613A1 (en) 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US6383594B2 (en) * 1998-10-07 2002-05-07 Johns Manville International, Inc. Pre-cut fibrous insulation for custom fitting building cavities of different widths
DE19847618A1 (de) 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6502135B1 (en) 1998-10-30 2002-12-31 Science Applications International Corporation Agile network protocol for secure communications with assured system availability
DE19853985A1 (de) 1998-11-23 2000-05-25 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19855440A1 (de) 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
DE19856147A1 (de) 1998-12-04 2000-06-08 Knoll Ag Teilbare feste Dosierungsformen und Verfahren zu ihrer Herstellung
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
AT407111B (de) 1998-12-22 2000-12-27 Gergely Dr & Co Zucker- und/oder zuckeralkoholhältiges matrixmaterial und verfahren zu seiner herstellung
WO2000040220A1 (en) 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
DE19901383A1 (de) 1999-01-15 2000-07-20 Knoll Ag Verfahren zur Herstellung unterschiedlicher fester Dosierungsformen
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP1027887B1 (en) 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
US6440946B1 (en) * 1999-02-25 2002-08-27 Takeda Chemical Industries, Ltd. Multiple-agents-binding compound, production and use thereof
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
US6497905B1 (en) 1999-03-24 2002-12-24 R.P. Scherer Technologies, Inc. Aqueous solubility pharmaceutical formulations
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
FR2793689B1 (fr) 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
NL1012300C2 (nl) 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.
FR2795326B1 (fr) 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
DE19930454A1 (de) 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
DE19934610A1 (de) 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
DE19943501A1 (de) 1999-09-10 2001-03-15 Basf Ag Unterwassergranulation wirkstoffhaltiger Schmelzen
SE9903236D0 (sv) 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
ES2288872T3 (es) 1999-09-29 2008-02-01 R.P. Scherer Technologies, Inc. Granulaciones con celulosa hidrolizada de sales de medicamentos.
DE19949897A1 (de) 1999-10-15 2001-04-19 Rainer Rogasch Formkörper und Verfahren zu dessen Herstellung
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6372259B1 (en) 1999-11-10 2002-04-16 University Of Iowa Research Foundation Palatable, sustained release drug granules
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
JP4815085B2 (ja) 1999-11-12 2011-11-16 アボット・ラボラトリーズ 固体分散体医薬製剤
DE19958007A1 (de) 1999-12-02 2001-06-07 Roehm Gmbh Spritzgußverfahren für (Meth)acrylat-Copolymere mit teritiären Ammoniumgruppen
DE19960494A1 (de) * 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
DE19961334A1 (de) 1999-12-17 2001-06-21 Roehm Gmbh Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
EP2415462A1 (en) 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
EA006402B1 (ru) * 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
GEP20043334B (en) * 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
DE10000792A1 (de) 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
US7029700B2 (en) 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US6777274B2 (en) * 2000-01-25 2004-08-17 Samsung Electronics Co., Ltd. Low temperature polycrystalline silicon type thin film transistor and a method of the thin film transistor fabrication
GB0003782D0 (en) * 2000-02-17 2000-04-05 Dumex Ltd As Process
GB0005016D0 (en) 2000-03-01 2000-04-26 Jumik Technologies Limited PVA-Containing compositions
DE60119905T2 (de) 2000-03-09 2007-01-11 Ohio State University Research Foundation, Columbus Verfahren zur Herstellung von Feststoffdispersionen
GT200100039A (es) 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
DE10013289A1 (de) 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
DE10021539C1 (de) 2000-05-03 2002-02-28 Henkel Kgaa Vorrichtung zur Sprühtrocknung von lösungsmittelhaltigen Zusammensetzungen
KR20010107754A (ko) * 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10026699A1 (de) 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
AU2001279284A1 (en) 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
US20100010101A1 (en) * 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
IT1318618B1 (it) 2000-07-10 2003-08-27 A C R Applied Coating Res S A Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi.
AU2001289653A1 (en) 2000-07-14 2002-01-30 Universiteit Gent Composite solid shaped articles for the controlled delivery of biologically active ingredients
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
EP1308156A4 (en) 2000-08-11 2009-07-15 Eisai R&D Man Co Ltd AGGREGATE SOLID DISPERSION WITH IMPROVED SOLUBILITY
US6372905B1 (en) * 2000-08-31 2002-04-16 Abbott Laboratories Processes and intermediates for preparing retroviral protease inhibitors
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
FR2814366A1 (fr) * 2000-09-22 2002-03-29 Rhodia Chimie Sa Procede de granulation de matieres actives par extrusion basse pression pour l'obtention de granules directement compressibles
US20040013736A1 (en) * 2000-09-25 2004-01-22 Tomio Nakano Process for producing medicinal solid dispersion
JP2004509739A (ja) 2000-09-27 2004-04-02 ベリオン　インコーポレイテッド 即時水溶解性カプセルおよびその製法
US6579521B2 (en) * 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
AU2002226098A1 (en) 2000-10-30 2002-05-15 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
GB0026593D0 (en) * 2000-10-31 2000-12-13 Quadrant Holdings Cambridge Derivatised carbohydrates and their use in solid delivery systems
AU2002212102A1 (en) 2000-11-08 2002-05-21 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
DK1343530T3 (da) 2000-11-09 2007-10-15 Astrazeneca Ab Oral farmaceutisk sammensætning, der indeholder en blokcopolymer
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
GB0029843D0 (en) 2000-12-07 2001-01-24 Univ Belfast Drug delivery system
US20050175687A1 (en) 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US7842308B2 (en) 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
WO2002064121A1 (en) 2001-02-13 2002-08-22 Astrazeneca Ab Novel modified released formulation
GB0104752D0 (en) 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
JP2005511481A (ja) * 2001-05-01 2005-04-28 アボット・ラボラトリーズ ロピナビルを含有する組成物及び薬剤のバイオアベイラビリティーを高めるための方法
HRP20030873B1 (en) 2001-05-03 2006-04-30 F. Hoffmann - La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
AR033711A1 (es) 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
EP1390015A1 (en) 2001-05-31 2004-02-25 Cima Labs Inc. Taste-masking of highly water-soluble drugs
DE10127134A1 (de) 2001-06-05 2002-12-12 Roehm Gmbh verfahren zur Herstellung von Formkörpern aus (Meth)acrylat-Copolymeren mittels Spritzguß
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030212102A1 (en) 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
WO2003000226A2 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA03011922A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen un dispersion solida de un farmaco ligeramente soluble en una matriz y plimero mejorador de solubilidad.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
SK15742003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutická kompozícia zahrnujúca adsorbát amorfného liečiva
JP2004534822A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 低溶解度および／または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
RU2330642C2 (ru) * 2001-07-06 2008-08-10 Лайфсайкл Фарма А/С Регулируемая агломерация
US20030044474A1 (en) 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
FR2828380B1 (fr) 2001-08-10 2005-07-29 Fontarome Composition a structure composite contenant des substances aromatiques et/ou des substances non aromatiques volatiles et/ou sensibles aux agents exterieurs, et son procede de fabrication
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
EP1429734B1 (en) 2001-09-21 2007-12-26 Egalet A/S Controlled release solid dispersions of carvedilol
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
MXPA04002992A (es) 2001-09-28 2005-06-20 Johnson & Johnson Composicion comestible y forma de dosificacion que comprende una cubierta comestible.
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
DE10151290A1 (de) 2001-10-22 2003-04-30 Roehm Gmbh Verfahren zur Herstellung von wirkstoffhaltigen Pellets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
WO2003041690A2 (en) 2001-10-29 2003-05-22 Therics, Inc. Three-dimensional suspension printing of dosage forms
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
JP2003146869A (ja) 2001-11-14 2003-05-21 Scg:Kk 口腔内崩壊型固形製剤及びその製造方法
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
AU2002346472A1 (en) 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
US7179488B2 (en) * 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
EP1509204A4 (en) 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co AGGLOMERATED PARTICLES WITH AN ACTIVE SUBSTANCE PREPARED WITH MELTED MICROCRYSTALLINE CELLULOSE
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
CA2469718A1 (en) 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
MXPA04006545A (es) 2002-01-03 2004-10-04 Smithkline Beecham Corp Nuevas formas de dosificacion farmaceutica y metodo para producir las mismas.
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
MXPA04007428A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
MXPA04007438A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
DE10208344A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
EP1515699B1 (en) 2002-03-07 2009-02-04 Eurand Pharmaceuticals Ltd. Process for loading and thermodynamically activating drugs on polymers by means of supercritical fluids
ATE374598T1 (de) 2002-03-15 2007-10-15 Alrise Biosystems Gmbh Mikropartikel und verfahren zur deren herstellung
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10213977A1 (de) 2002-03-28 2003-10-16 Krauss Maffei Kunststofftech Verfahren zum Herstellen von Wirkstoffe enthaltenden Formkörpern
DE20308436U1 (de) 2002-04-05 2003-09-18 Euroceltique S.A., Luxemburg/Luxembourg Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
CN1646171B (zh) 2002-04-19 2010-05-26 诺瓦提斯公司 新型生物材料、其制备和用途
US20030203027A1 (en) 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
AU2003234439A1 (en) * 2002-05-07 2003-11-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AR039744A1 (es) 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AU2003260239A1 (en) * 2002-06-26 2004-01-19 Tuo Jin Solid dosage forms for rapid dissolution of poorly soluble drugs
US7155459B2 (en) * 2002-06-28 2006-12-26 Miccrosoft Corporation Time-bound database tuning
EP1521571A1 (en) 2002-07-04 2005-04-13 Janssen Pharmaceutica N.V. Solid dispersion comprising two different polymer matrixes
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
TW200410714A (en) * 2002-08-07 2004-07-01 Smithkline Beecham Corp Electrospun amorphous pharmaceutical compositions
PL375345A1 (en) 2002-08-12 2005-11-28 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
WO2004014450A1 (en) 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery system including a hydrophobic cellulose derivate
CA2495172A1 (en) 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
PT1553927E (pt) * 2002-09-11 2010-11-22 Elan Pharma Int Ltd Composições de agentes activos em nanopartículas estabilizadas em gel
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
DE10247037A1 (de) 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
FR2846557B1 (fr) * 2002-10-30 2007-06-08 Statice Sante Structure implantable pour la liberation prolongee et controlee d'un principe actif
AU2003304108B2 (en) 2002-10-30 2007-03-22 Spherics, Inc. Nanoparticulate bioactive agents
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004054568A1 (en) 2002-12-17 2004-07-01 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US6872799B2 (en) 2002-12-18 2005-03-29 Ethicon, Inc. Functionalized polymers for medical applications
JP2006513238A (ja) 2002-12-19 2006-04-20 ファルマシア・コーポレーション 吸湿性薬物を含む非‐吸湿性製剤
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
ITMI20022748A1 (it) 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
AU2003205543A1 (en) 2003-01-14 2004-08-10 Lifecycle Pharma A/S Dry dispersions
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
US20040258752A1 (en) 2003-01-31 2004-12-23 Paruthi Manoj Kumar Taste masking pharmaceutical composition and process for its preparation
WO2004069138A2 (en) 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US20040156894A1 (en) 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
WO2004071494A2 (en) 2003-02-13 2004-08-26 Phares Pharmaceutical Research N.V. Lipophilic compositions
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
US20040208928A1 (en) 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
EP1617842A1 (en) * 2003-04-22 2006-01-25 Dr. Reddy's Laboratories Ltd. Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
GB0310300D0 (en) 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
WO2004100883A2 (en) 2003-05-06 2004-11-25 Bpsi Holdings, Inc. Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same
JP2004339162A (ja) 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd 難溶性薬物を含む医薬用固形製剤とその製造方法
EP1479381A1 (en) 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
MXPA05012821A (es) * 2003-05-28 2006-02-13 Nektar Therapeutics Formulacion farmaceutica que comprende un agente activo insoluble en agua.
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
WO2004112755A1 (en) 2003-06-18 2004-12-29 John Michael Newton Controlled release devices with lumens
WO2005000237A2 (en) 2003-06-25 2005-01-06 University Of Tennessee Research Foundation Granules containing biologically active substances
KR20070087194A (ko) 2003-07-11 2007-08-27 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
TW200526274A (en) 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
BR0302523A (pt) 2003-07-23 2005-04-05 Cristalia Prod Quimicos Farm Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
US7645474B1 (en) * 2003-07-31 2010-01-12 Advanced Cardiovascular Systems, Inc. Method and system of purifying polymers for use with implantable medical devices
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
WO2005014163A1 (en) 2003-08-04 2005-02-17 Camurus Ab Method for loading amphiphile particles with active agents
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2007501224A (ja) * 2003-08-05 2007-01-25 フジ フォト フィルム ビー．ブイ． 安定剤としての組換え又は合成ゼラチン様タンパク質の、凍結乾燥医薬組成物中の使用
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
EP1675576A1 (en) 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
MXPA06004005A (es) 2003-10-08 2006-06-28 Vertex Pharma Moduladores de transportadores con casete de union con atp.
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
US8647668B2 (en) 2003-10-15 2014-02-11 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
RU2006118359A (ru) * 2003-10-27 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Комбинации для лечения вирусного гепатита с (hcv)
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
JP2007518669A (ja) 2003-12-15 2007-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ ｐＨ感受性ポリマーを含む風味マスクされる医薬組成物
WO2005115343A2 (de) 2004-05-28 2005-12-08 Abbott Gmbh & Co. Kg Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102004040104A1 (de) 2004-08-18 2006-02-23 Basf Ag Verwendung von amphiphilen Copolymerisaten als Solubilisatoren
GB0501835D0 (en) 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
US20090104269A1 (en) 2005-02-11 2009-04-23 Brian Graham Nanoformulations
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
JP2008542305A (ja) 2005-06-03 2008-11-27 ホリズン サイエンス ピーティーワイ リミテッド 配送システム
WO2007002041A2 (en) 2005-06-21 2007-01-04 Foster Corporation Drug-filled polymer films
JP2009502841A (ja) 2005-07-26 2009-01-29 グラクソ グループ リミテッド 脂質をベースにした製剤の腸溶性ポリマー中へのカプセル化
US20090028938A1 (en) 2005-08-08 2009-01-29 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
EP1915407A2 (de) 2005-08-11 2008-04-30 Basf Se Copolymere auf basis von n-vinylcaprolactam und deren verwendung als solubilisatoren
EP1942875B1 (en) 2005-08-24 2015-08-12 Rubicon Research Private Limited Controlled release formulation
US20070077305A1 (en) 2005-10-03 2007-04-05 Le Tien C Biocompatible polymeric matrix and preparation thereof
WO2007050631A2 (en) 2005-10-25 2007-05-03 Cima Labs Inc. Dosage form with coated active
ITMI20052461A1 (it) * 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
EP1986591A1 (en) 2006-02-10 2008-11-05 LG Household & Health Care Ltd. In-situ melting and gelling tablet composition for oral care
CA2647158C (en) 2006-03-23 2012-07-31 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
US7771632B2 (en) 2006-05-15 2010-08-10 American Leistritz Extruder Corp. Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets
WO2007141182A2 (de) 2006-06-07 2007-12-13 Basf Se Verwendung von vinylacetat-sulfonat-copolymeren als solubilisatoren für in wasser schwerlösliche verbindungen
US8343548B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
EP2112925A4 (en) 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
WO2009013202A1 (de) 2007-07-26 2009-01-29 Basf Se Verfahren zur herstellung von durch pfropfpolymerisation in lösung erhaltenen copolymeren auf basis von polyethern in fester form
EP2022805A3 (en) * 2007-08-03 2009-02-25 Basf Se Copolymers based on N-vinyllactams and olefins as their use as solubilizers for slightly water-soluble compounds
MY185299A (en) 2007-10-11 2021-04-30 Philip Morris Products Sa Smokeless tobacco product
WO2009113522A1 (ja) * 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2010017053A1 (en) 2008-08-06 2010-02-11 Isp Investments, Inc. Solid excipient compositions
GB0815852D0 (en) 2008-09-01 2008-10-08 Unilever Plc Improvements relating to pharmaceutical compositions
CA2737247C (en) * 2008-09-15 2016-10-11 Labopharm Inc. Starch-based microparticles for the release of agents disposed therein
KR20110110097A (ko) 2008-10-28 2011-10-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 수난용성 성분을 위한 메조포러스 물질 부형제
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
WO2010078429A1 (en) 2008-12-30 2010-07-08 Impax Laboratories, Inc. Pharmaceutical dosage forms and methods of manufacturing same
CN101444494B (zh) 2008-12-31 2011-03-30 江苏大学 难溶性药物高效长效缓释制剂及其制法
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2311435A1 (en) 2009-10-07 2011-04-20 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
WO2011090724A2 (en) 2009-12-29 2011-07-28 Impax Laboratories, Inc. Gastroretentive solid oral dosage forms with lipid-based low-density excipient
KR20130010482A (ko) 2010-03-26 2013-01-28 다우 글로벌 테크놀로지스 엘엘씨 용융-압출된 다중층 필름
US20110288181A1 (en) 2010-05-21 2011-11-24 Basf Se Preparations of biologically active substances with enlarged surface based on amphiphilic copolymers
BR112012031667A2 (pt) 2010-06-14 2016-11-08 Dow Global Technologies Llc composição

Also Published As

Publication number Publication date
UY29391A1 (es) 2006-10-02
DOP2019000185A (es) 2019-08-15
CY1120377T1 (el) 2019-07-10
PE20100123A1 (es) 2010-03-03
CL2017001847A1 (es) 2018-04-27
US20050143404A1 (en) 2005-06-30
PH12012501811A1 (en) 2013-09-30
EA200701790A1 (ru) 2008-02-28
MX2007010275A (es) 2007-11-08
JP2008531565A (ja) 2008-08-14
AR077411A2 (es) 2011-08-24
DK2283844T3 (en) 2018-11-26
TR201809084T4 (tr) 2018-07-23
CA2821046C (en) 2018-04-24
RS57378B1 (sr) 2018-08-31
GT200600295A (es) 2007-09-13
BR122012031169A2 (pt) 2015-07-07
EP2283844B1 (en) 2018-08-01
JP5087409B2 (ja) 2012-12-05
UA89220C2 (ru) 2010-01-11
IL185390A0 (en) 2008-02-09
DK2206500T3 (en) 2018-07-16
HRP20181819T1 (hr) 2019-01-11
CN101163479B (zh) 2011-12-07
EP3482762A1 (en) 2019-05-15
ES2694073T3 (es) 2018-12-17
PT2206500T (pt) 2018-07-04
CA2598827C (en) 2013-09-24
PT2283844T (pt) 2018-11-16
SI2206500T1 (en) 2018-08-31
IL185390A (en) 2017-06-29
PL2206500T3 (pl) 2018-09-28
ZA200707022B (en) 2009-08-26
CL2009001844A1 (es) 2009-12-11
US8377952B2 (en) 2013-02-19
PL2283844T3 (pl) 2019-03-29
TWI381840B (zh) 2013-01-11
AR055734A1 (es) 2007-09-05
CR9353A (es) 2008-03-18
DOP2006000050A (es) 2006-11-15
TW200716119A (en) 2007-05-01
CL2013003554A1 (es) 2014-05-09
GEP20105083B (en) 2010-09-27
KR20070114294A (ko) 2007-11-30
EP2206500A1 (en) 2010-07-14
HUE038073T2 (hu) 2018-09-28
EP2206500B1 (en) 2018-03-28
LT2283844T (lt) 2018-11-12
EP2283844A1 (en) 2011-02-16
AU2006216856A1 (en) 2006-08-31
TR201816268T4 (tr) 2018-11-21
BRPI0609173A2 (pt) 2010-02-23
CN101163479A (zh) 2008-04-16
SV2007002427A (es) 2007-01-08
WO2006091529A3 (en) 2007-02-08
EA014446B1 (ru) 2010-12-30
AU2006216856B2 (en) 2012-03-08
MY146247A (en) 2012-07-31
US20080299203A1 (en) 2008-12-04
HRP20180999T1 (hr) 2018-08-10
LT2206500T (lt) 2018-07-10
CY1122777T1 (el) 2020-10-14
US20130004578A1 (en) 2013-01-03
WO2006091529A2 (en) 2006-08-31
NO20074807L (no) 2007-09-21
SI2283844T1 (sl) 2018-12-31
RS57938B1 (sr) 2019-01-31
ES2675548T3 (es) 2018-07-11
CA2598827A1 (en) 2006-08-31
EP1855683A2 (en) 2007-11-21
KR101429024B1 (ko) 2014-08-12
CA2821046A1 (en) 2006-08-31
HUE041591T2 (hu) 2019-05-28
UY32116A (es) 2011-04-29
GT200600295AA (es) 2012-03-12
NZ599361A (en) 2013-10-25
NZ560829A (en) 2010-12-24

Similar Documents

Publication Publication Date Title
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
NO20073722L (no) Farmasoystiske sammensetniger omfattende bendamustin
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
MY143795A (en) Tetrahydropyridoindole derivatives
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CR8569A (es) Inhibidores de integrasa de vih
CL2009000902A1 (es) Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica.
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
UY29377A1 (es) Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos.
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
RU2009120992A (ru) Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции
GT200600135A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales
CL2011003144A1 (es) Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05).
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
MX2019015733A (es) Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
EP1993567A4 (en) PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
MX2018000021A (es) Composiciones multifasicas.
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.

Legal Events

Date Code Title Description
FG Grant, registration